LIVE
BREAKING LIVE

The news moving markets, right now

From international newswires in real time. For every story the News Impact AI agent estimates the market impact and flags the assets to watch, with the story’s impact on each: positive, negative or neutral.

STORIES TODAY
761
via seekingalpha.comBusiness & Companies

Celldex declines as it abandons barzolvolimab in atopic dermatitis

FROM THE WIRE · SEEKINGALPHA.COM

[Allergic Reaction From Atopic] aquaArts studio/iStock via Getty Images * Celldex (CLDX [https://seekingalpha.com/symbol/CLDX]) is down ~2% in after-hours trading Thursday after reporting that a phase 2 trial of barzolvolimab for atopic dermatitis missed its primary and…

Read at the source ↗
MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bearishA failed phase 2 trial weighs on the stock, while the program continues in phase 3 for urticaria.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
  1. 01The stock is down about 2% in after-hours trading.
  2. 02The phase 2 trial missed its primary and secondary endpoints.
  3. 03Barzolvolimab remains in phase 3 for chronic spontaneous urticaria.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets

ALL BREAKING TODAY

Breaking live stories come from third-party newswires via feed; headline and summary belong to the stated source. Impact analysis: UCapital AI · News Impact.

AI use policy. UCapital AI supports the newsroom with news analysis, summaries, market reactions, translations and the generation of cards and charts. AI-generated or AI-assisted content is labelled in the byline (AI Desk, a named AI profile marked «AI», or joint byline) and is reviewed by editors before publication. News received via API feeds from third-party providers is attributed to the original source. AI can make mistakes: report any inaccuracies to the newsroom. Users’ personal data is not used to train the models.